It is now evident that P450 enzymes metabolize key cellular constituents, including long-chain fatty acid such as arachidonic acid (AA), leukotrienes (LT) such as LTB4, and other eicosanoids. P450-mediated oxidation of these lipid-derived endobiotics results in products with potent effects on ion transport and vasomotion, or results in their inactivation, as observed with the proinflammatory LTs and prostanoids. Yet, the contribution of specific P450s to the formation and/or catabolism of fatty acids and eicosanoids remain unclear, as does the regulation of these endobiotic-metabolizing enzymes. In this competitive renewal proposal, we will continue our studies on P450 enzymes comprising the CYP4A and CYP4F gene subfamilies (i.e., CYP4F/A P450s) which, in human liver and kidney, function as the principle fatty acid and eicosanoid omega-hydroxylases. We will extend our studies on arachidonic acid (AA) and leukotriene B4 (LTB4) omega-hydroxylation by CYP4F2 and CYP4A11 to now include CYP4F3b, CYP4F11, and CYP4F12, as the latter CYP4F gene products, which have recently been cloned, can catalyze the same eicosanoid-metabolizing reactions, at least in heterologous expression systems. We will clarify the discrepancies described in substrate specificities between native and recombinant human CYP4F/A P450s, especially with regards to 20-HETE formations, in light of this oxygenated AA product's physiological importance. We will determine whether the CYP4F omega-hydroxylases embody an important control point in hepatic inflammatory processes and/or disease states by gauging their capacity to convert LTB4 to an oxygenated metabolite which, unlike its precursors, is devoid of all inflammatory properties. The molecular basis for CYP4A11 catalysis of AA omega-hydroxylation in kidney but not in liver, despite its expression in both tissues, will be pursued. RNA and protein quantitation studies will be performed to a) determine expression of the diverse CYP4F/A proteins in liver and kidney and; b) to assess whether these P450s are localized in kidney nephronic regions implicated in blood pressure control and/or ion transport. Primary cultures of human hepatocytes will be employed to assess if fatty acids or hypolipidemic agents capable of altering circulating fatty acid levels are also capable of influencing expression of hepatic CYP4F/A P450s, and if ethanol, which alters the AA content in cellular membranes, induces these CYP4F/A proteins as it does CYP2E1.
Our aims are to define the role of the human CYP4F/A P450 enzymes proteins in the disposition of endogenous fatty acids and bioactive eicosanoids and, ultimately, to reveal if variations in the metabolism of such agents by members of the CYP4 gene family could perturb normal physiological processes in the liver or kidney, such as blood flow, ion transport, the control of inflammation, and the intracellular flux of fatty acids.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
2R01AA007842-12A1
Application #
6588001
Study Section
Special Emphasis Panel (ZRG1-SSS-3 (04))
Program Officer
Velazquez, Jose M
Project Start
1993-04-01
Project End
2007-02-28
Budget Start
2003-03-01
Budget End
2004-02-29
Support Year
12
Fiscal Year
2003
Total Cost
$348,750
Indirect Cost
Name
Hackensack University Medical Center
Department
Type
DUNS #
042797571
City
Hackensack
State
NJ
Country
United States
Zip Code
07601
Savas, Uzen; Machemer, Daniel E W; Hsu, Mei-Hui et al. (2009) Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. J Biol Chem 284:16541-52
Hirani, Vandana; Yarovoy, Anton; Kozeska, Anita et al. (2008) Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies. Arch Biochem Biophys 478:59-68
Dhar, Madhurima; Sepkovic, Daniel W; Hirani, Vandana et al. (2008) Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11. J Lipid Res 49:612-24
Raucy, Judy L; Lasker, Jerome; Ozaki, Kazuaki et al. (2004) Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci 79:233-41
Hirani, Vandana N; Raucy, Judy L; Lasker, Jerome M (2004) Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 32:1462-7
Raucy, Judy L; Mueller, Lisa; Duan, Kui et al. (2002) Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 302:475-82
Lasker, J M; Chen, W B; Wolf, I et al. (2000) Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 275:4118-26
Cummings, B S; Lasker, J M; Lash, L H (2000) Expression of glutathione-dependent enzymes and cytochrome P450s in freshly isolated and primary cultures of proximal tubular cells from human kidney. J Pharmacol Exp Ther 293:677-85
Wester, M R; Lasker, J M; Johnson, E F et al. (2000) CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 28:354-9
Pan-Zhou, X R; Cretton-Scott, E; Zhou, X J et al. (1998) Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3'-azido-3'-deoxythymidine (AZT) to 3'-amino-3'-deoxythymidine. Biochem Pharmacol 55:757-66

Showing the most recent 10 out of 26 publications